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control group stating the fact that dietary antioxidants does not play a 
major role in prevention of cancer but it delays the cancer progression 
as conﬁrmed and stated by the research conducted elsewhere (5). Our 
study concludes that in changing lifestyle cancer is one of the major 
community health problems and it can only be prevented with regular 
intake of antioxidant vitamins and advocating healthy habits by say-
ing to avoid smoking, tobacco, drinking, roasted food, air pollution 
environment etc. Nepal being a poor developing country with scientiﬁc 
research and molecular biochemistry is in grass-root stage, the authors 
feels that this current study would show some light for the future re-
search and encourage the habit of doing original work and contribute to 
the developing nation in the ﬁeld of molecular biochemistry. 
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Background: Recent studies have shown elevated levels of circulating 
plasma DNA (cpDNA) detected in patients with lung cancer, as com-
pared to cancer-free controls. Here we tested the hypothesis whether 
cpDNA could serve as a screening tool in the detection of HRCT and 
FDG-PET scan occult ﬂat type 1 cm2 mucosal lesions sampled using 
autoﬂuorescence bronchoscopy, histologically conﬁrmed as intralumi-
nal squamous cell lung cancer (ISCC) and to differentiate its presence 
from precursors lesions e.g. severe dysplasia and carcinoma in situ. 
Methods: From January 2004 till March 2006 blood specimens were 
prospectively collected. After sampling, plasma was separated by 
centrifuging and stored at -80 °C. DNA was extracted using QIAamp 
DNA mini kit (Qiagen®, Leusden, The Netherlands). Quantiﬁcation of 
cpDNA was performed by real-time quantitative PCR. The specimens 
with a yield between 10% and 100% of spiked plasmid DNA were 
evaluated and data were correlated to the WHO classiﬁcation by a pan-
el of pathologists of the histology specimens. Blood from four groups 
of patients and one control group were tested. Cohort 1 = microinvasive 
ISCC, cohort 2 = possibly ISCC, cohort 3 = severe dysplasia/carcinoma 
in situ, cohort 4 = bulky stage IIa- stage IV NSCLC (considered as 
positive controls) and cohort 5 = cancer-free volunteers (considered as 
negative controls). Values are presented as median and range. Compari-
sons between cohorts were performed with the Mann-Whitney U test, 
P<0.05 was considered statistically signiﬁcant. 
Results: cpDNA levels are presented in Table 1. Only the positive and 
negative control cohorts showed a signiﬁcant difference in cpDNA 
levels (P<0.013). No signiﬁcant differences in cpDNA levels between 
cohorts 1, 2 and 3 relative to cohorts 4 and 5 were seen. 
Conclusion: Quantiﬁcation of plasma DNA can neither be used as a 
screening tool, nor to indicate the presence of high-grade dysplastic 
lesions, carcinoma in situ and early stage microinvasive ISCC. It is not 
an early marker for the earliest stages of squamous cell lung cancer. 
Table 1. cpDNA levels (median, range) per cohort
Cohort (n) WHO histology classiﬁcation Median (range) cpDNA (ng/μl)
1 (5) microinvasive ISCC 2.93# (0.50-12.46)
2 (9) Possibly ISCC 2.14 (1.37-5.55)
3 (4) Severe Dysplasia/CIS 3.68 (2.38-5.09)
4 (10) Positive Controls 5.52* (1.61-12.17)
5 (10) Negative Controls 1.72#,* (0.97-2.36)
* P<0.013   # P<0.540
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Background: The present study aimed to estimate mean sojourn time 
(MST) of lung cancer by computed tomography (CT), an average dura-
tion period in which tumor can be asymptotically detected, taking into 
account modality, smoking and possible ethnic effect. 
Methods: Based on literature review, prospective trials with complete 
prevalent & incident screen detected cases and interval cases were 
identiﬁed (trial number=5) and data were retrieved (total participants n 
=40488). The MST for the natural history of lung cancer underpinning 
a three-state Markov model was estimated with a Bayesian approach. 
Posterior distributions, from which we drew inferences on MST, were 
derived from 5,000 iterations after 1,000 burn-in of WinBUGS pro-
gram. From the 5000 samples, we used the median value as an overall 
summary data and 2.5th and 97.5th percentiles as the lower- and upper-
bounds of the 95% credible intervals, and standard deviation was also 
available. For estimation of the overall effect, a random effect model 
was applied. 
Results: The estimated MST (year, with 95%CI) by screening CT in 
individual trial ranged from 1.01 (0.37~3.7) to 3.88 (3.47~4) (table 1). 
The overall estimated MST for lung cancer was 2.35 (0.77-3.69) years. 
The overall estimation of MST by the three pure Western trials was 
1.96 (0.29~3.5) years, which was longer than the only pure Eastern 
trial (1.5(1~2.55) years). The estimated MST was shorter for eastern 
smoker (estimated median to be within 1.7~1.94 years) in contrast to 
eastern non-smoker (estimated median to be within 1.81~2.04 years), 
and also shorter for lung cancer screened by chest x-ray (0.97, 95%CI: 
0.49-2.8). 
Conclusions: Our estimated MST of lung cancer by screening CT was 
close to reported MST estimation of breast cancer by screening mam-
mography(1.8 (1.33~2.45), Myles JP 2003), which suggests screening 
tool with CT may be effective in early detection of lung cancer.
Author (year)
Gohagan JK 
et al (2005)
Henschke C I 
et al (2006)
Diederich S 
et al (2004)
Sone S et al 
(2001)
Pastorino U 
et al (2003)
MST(year) 2.8 3.88 1.01 1.5 1.9
95% conﬁdence 
itnerval 1.5~3.9 3.47~4 0.37~3.7 1~2.55 0.97~3.69
median & 95% conﬁdence interval of estimated MST in individual trial
